- Home
- RNR vs ASND Comparison
RNR vs ASND Comparison
Compare RNR & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNR | ASND |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | Bermuda | Denmark |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 12.2B |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RNR | ASND |
|---|---|---|
| Price | $266.10 | $205.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $291.73 | $256.27 |
| AVG Volume (30 Days) | 387.6K | ★ 640.2K |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 34.70 | N/A |
| Revenue | ★ $12,214,870,000.00 | $758,592,045.00 |
| Revenue This Year | N/A | $99.74 |
| Revenue Next Year | N/A | $79.40 |
| P/E Ratio | $7.63 | ★ N/A |
| Revenue Growth | N/A | ★ 97.46 |
| 52 Week Low | $219.00 | $118.03 |
| 52 Week High | $290.78 | $223.19 |
Technical Indicators
Market Signals| Indicator | RNR | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 49.03 |
| Support Level | $261.38 | $198.30 |
| Resistance Level | $263.87 | $218.50 |
| Average True Range (ATR) | 5.15 | 9.16 |
| MACD | 0.09 | -0.64 |
| Stochastic Oscillator | 64.18 | 28.05 |
Price Performance
Historical ComparisonAbout RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.